The value of tumor markers in men with metastatic prostate cancer undergoing [ Lu]Lu-PSMA therapy.

Background: Currently, prostate-specific membrane antigen-radioligand therapy (PSMA-RLT) is considered a last-line treatment option in advanced castration-resistant prostate cancer. Despite these patients' poor prognosis, accurate estimation of their overall survival (OS) is essential to determine whether benefits exist from the treatment and whether the loss of valuable time and unnecessary side effects can be avoided. The aim of the present study is to evaluate whether various biochemical markers can predict OS in men undergoing PSMA-RLT and whether the changes assessed after PSMA-RLT correlate with the OS.

Outcome and safety of rechallenge [Lu]Lu-PSMA-617 in patients with metastatic prostate cancer.

Background: Data are sparse regarding the feasibility of radioligand therapy (RLT) with [Lu]Lu-PSMA-617 as a retreatment. We aimed to assess the outcome and safety of rechallenge PSMA-RLT in patients with progressive prostatic cancer who previously benefited from this therapy.

Materials And Methods: Patients who received rechallenge therapy at our department from January 2015 to March 2018 were assessed.